

Point of Care Molecular Diagnostics Market by Product (Assays, Kits, Instruments, Software), Application (Respiratory Diseases, HAIs, Cancer, STDs, Hepatitis), Technology (RT-PCR, INAAT), End User (Clinics, Hospitals, ICUs) - Global Forecast to 2028

Market Report | 2023-06-14 | 207 pages | MarketsandMarkets

AVAILABLE LICENSES:

- Single User \$4950.00
- Multi User \$6650.00
- Corporate License \$8150.00
- Enterprise Site License \$10000.00

Report description:

The global point-of-care molecular diagnostics market size is projected to reach USD 3.4 billion by 2028 from USD 2.0 billion in 2023, at a CAGR of 10.6% during the forecast period. Market growth is driven by factors such as the increasing prevalence of infectious diseases and cancer, rising focus on decentralized diagnostics and increasing R&D funding, increasing awareness on the early detection of infectious diseases, and the increasing use of POC diagnostic tests. On the other hand, stringent and time-consuming regulatory policies that significantly increase the product launch cycle may challenge market growth post their commercialization.

"The assays & kits accounted for the highest growth rate in the point-of-care molecular diagnostics market, by product & service, during the forecast period"

The point-of-care molecular diagnostics market is segmented into assays & kits, instruments & analyzers and software and services. The assays & kits segment accounted for the highest growth rate in the point-of-care molecular diagnostics market in 2022. The requirement assays & kits in large numbers compared to instruments is the main factor contributing to this segment's high growth rate. This segment's market growth can also be attributed to repeat purchases of assays & kits compared to instruments.

"Hospitals & ICUs segment accounted for the highest CAGR"

The point-of-care molecular diagnostics market is divided into various end-user segments, including physicians' offices, hospitals & ICUs, research institutes, and other end users. In 2022, the hospitals & ICUs segment experienced the most significant growth rate. One of the primary advantages of utilizing point-of-care molecular tests in hospitals or clinical settings, as opposed to

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

traditional point-of-care tests, is their ability to provide faster turnaround times and increased accuracy. The hospitals & ICUs segment's substantial market share can be attributed to the growing number of hospitals and the high demand for diagnostic products within these healthcare facilities.

"Asia Pacific: The fastest-growing region point-of-care molecular diagnostics market"

The global market for point-of-care molecular diagnostics is categorized into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Among these regions, the Asia Pacific region is anticipated to exhibit the highest compound annual growth rate (CAGR) throughout the forecast period. The remarkable growth in the Asia Pacific market can be attributed to several factors. These include the proactive efforts by governments to raise awareness about early disease detection and promote regular health check-ups, the increasing healthcare expenditure in the region, the rising number of hospitals and clinical diagnostic laboratories in countries like India and China, and the strengthening research capabilities in diagnostic procedures across India, China, and Japan.

The primary interviews conducted for this report can be categorized as follows:

-□By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 - 30%

-□By Designation: C-level - 27%, D-level - 18%, and Others - 55%

-□By Region: North America - 51%, Europe - 21%, Asia Pacific - 18% and Latin America 6% and Middle East & Africa 4%

Prominent companies Abbott Laboratories (US), F. Hoffmann-La Roche Ltd. (Switzerland), bioMérieux SA (France), Danaher Corporation (US), QIAGEN N.V. (Netherlands), QuidelOrtho Corporation (US), Co-Diagnostics, Inc. (US), Biocartis NV (Belgium), Meridian Bioscience, Inc. (US), Thermo Fisher Scientific, Inc. (US), Lucira Health, Inc. (US), Cue Health (US), OpGen, Inc. (US), Binx Health, Inc. (US), Molbio Diagnostics Pvt. Ltd. (India), Genomadix (Canada), Visby Medical, Inc. (US), QuikPath PTE Ltd. (Singapore), MD-Bio (US), QuantuMDx Group Ltd. (UK), Aidian Oy (Finland), GeneSTAT Molecular Diagnostics, LLC. (US), LabSystems Diagnostics Oy (Finland), Akonni Biosystems (US) and Curetis N.V. (Germany).

Research Coverage:

This research report categorizes the point of care molecular diagnostics market by product & service, technology, application, end user and region. The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the point-of-care molecular diagnostics market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, and services; key strategies; Contracts, partnerships, agreements, new product & service launches, mergers and acquisitions, and recent developments associated with the point of care molecular diagnostics market. Competitive analysis of upcoming startups in the point of care molecular diagnostics market ecosystem is covered in this report.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall point-of-care molecular diagnostics market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, challenges, and opportunities.

The report provides insights on the following pointers:

-□Analysis of key drivers, restraints, opportunities, and challenges influencing the growth of the point of care molecular diagnostics market.

-□Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the point of care molecular diagnostics market.

-□Market Development: Comprehensive information about lucrative markets - the report analyses the point of care molecular diagnostics market across varied regions.

-□Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the point of care molecular diagnostics market.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

-Competitive Assessment: In-depth assessment of market ranking, growth strategies and service offerings of leading players like Abbott Laboratories (US), F. Hoffmann-La Roche Ltd. (Switzerland), bioMerieux SA (France), Danaher Corporation (US), and QIAGEN N.V. (Netherlands), among others in the point of care molecular diagnostics market strategies.

Table of Contents:

1	INTRODUCTION	28
1.1	STUDY OBJECTIVES	28
1.2	MARKET DEFINITION	28
1.2.1	INCLUSIONS & EXCLUSIONS	29
1.3	MARKETS COVERED	29
1.3.1	POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET SEGMENTATION	29
1.3.2	GEOGRAPHIC SCOPE	30
1.3.3	YEARS CONSIDERED	30
1.4	CURRENCY	31
1.5	STUDY LIMITATIONS	31
1.6	STAKEHOLDERS	31
1.7	SUMMARY OF CHANGES	32
1.7.1	RECESSION IMPACT	32
2	RESEARCH METHODOLOGY	33
2.1	RESEARCH DATA	33
2.2	RESEARCH APPROACH	33
FIGURE 1 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET: RESEARCH DESIGN		33
2.2.1	SECONDARY DATA	34
2.2.1.1	Key data from secondary sources	34
2.2.2	PRIMARY DATA	35
2.2.2.1	Primary sources	36
2.2.2.2	Key data from primary sources	37
2.2.2.3	Key industry insights	38
2.2.2.4	Breakdown of primary interviews	38
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY- AND DEMAND-SIDE PARTICIPANTS		38
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION		39
2.3	MARKET SIZE ESTIMATION	39
2.3.1	BOTTOM-UP APPROACH	40
2.3.1.1	Approach 1: Company revenue estimation approach	40
FIGURE 4 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH		40
2.3.1.2	Approach 2: Presentations of companies and primary interviews	40
2.3.1.3	Growth forecast	41
2.3.1.4	CAGR projections	41
FIGURE 5 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS		41
2.3.2	TOP-DOWN APPROACH	41
FIGURE 6 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET: TOP-DOWN APPROACH		42
2.4	MARKET BREAKDOWN & DATA TRIANGULATION	43
FIGURE 7 DATA TRIANGULATION METHODOLOGY		43
2.5	MARKET SHARE ANALYSIS	43
2.6	STUDY ASSUMPTIONS	44
2.7	LIMITATIONS	44
2.8	RISK ASSESSMENT	45

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

2.8.1	RISK ASSESSMENT: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET	45
2.9	RECESSION IMPACT: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET	45
3	EXECUTIVE SUMMARY	47
FIGURE 8	POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023 VS. 2028 (USD MILLION)	47
FIGURE 9	POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023 VS. 2028 (USD MILLION)	48
FIGURE 10	POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION)	48
FIGURE 11	POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)	49
FIGURE 12	POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2023 VS. 2028 (USD MILLION)	50
4	PREMIUM INSIGHTS	51
4.1	POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET OVERVIEW	51
FIGURE 13	RISING ADOPTION OF POC DIAGNOSTICS TO SUPPORT MARKET GROWTH DURING FORECAST PERIOD	51
4.2	POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET SHARE, BY PRODUCT & SERVICE, 2023 VS. 2028	51
FIGURE 14	ASSAYS & KITS SEGMENT TO CONTINUE TO DOMINATE MARKET IN 2028	51
4.3	POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET SHARE, BY TECHNOLOGY, 2023 VS. 2028	52
FIGURE 15	RT-PCR SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD	52
4.4	POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET SHARE, BY APPLICATION, 2023 VS. 2028	52
FIGURE 16	RESPIRATORY DISEASES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD	52
4.5	POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET SHARE, BY END USER, 2023 VS. 2028	53
FIGURE 17	PHYSICIANS' OFFICES SEGMENT TO CONTINUE TO DOMINATE THE MARKET DURING THE FORECAST PERIOD	53
4.6	POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES	53
FIGURE 18	ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE IN POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET DURING FORECAST PERIOD	53
?		
5	MARKET OVERVIEW	54
5.1	INTRODUCTION	54
5.2	MARKET DYNAMICS	54
FIGURE 19	POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES	54
5.2.1	DRIVERS	55
5.2.1.1	Increasing prevalence of infectious diseases and cancer	55
5.2.1.2	Rising focus on decentralized diagnostics and increasing R&D funding	55
5.2.1.3	Growing awareness of the early detection of infectious diseases	56
5.2.1.4	Increasing use of POC diagnostic tests	57
5.2.2	RESTRAINTS	57
5.2.2.1	Unfavorable reimbursement scenario	57
5.2.2.2	High capital investments and low cost-benefit ratio	58
5.2.3	OPPORTUNITIES	58
5.2.3.1	Growing R&D activities in point-of-care molecular diagnostics testing	58
5.2.3.2	Growth opportunities in emerging economies	58
5.2.4	CHALLENGES	59
5.2.4.1	Stringent and time-consuming regulatory policies that significantly increase product launch cycle	59
5.2.4.2	Introduction of alternative technologies	60
5.3	PRICING ANALYSIS	60
TABLE 1	AVERAGE SELLING PRICE OF KEY PLAYERS, BY PRODUCT	60
5.4	PATENT ANALYSIS	61
FIGURE 20	PATENT ANALYSIS FOR POINT-OF-CARE MOLECULAR DIAGNOSTICS (JANUARY 2013-DECEMBER 2022)	61
5.4.1	LIST OF KEY PATENTS	62
5.5	VALUE CHAIN ANALYSIS	63

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

FIGURE 21	VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING & ASSEMBLY PHASE	63
5.6	SUPPLY CHAIN ANALYSIS	64
FIGURE 22	POINT-OF-CARE MOLECULAR DIAGNOSTICS: SUPPLY CHAIN ANALYSIS	65
5.7	ECOSYSTEM ANALYSIS	65
FIGURE 23	POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET: ECOSYSTEM ANALYSIS	65
5.7.1	POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET: ROLE IN ECOSYSTEM	66
5.8	PORTER'S FIVE FORCES ANALYSIS	67
TABLE 2	PORTER'S FIVE FORCES ANALYSIS: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET	67
5.8.1	THREAT OF NEW ENTRANTS	67
5.8.2	THREAT OF SUBSTITUTES	67
5.8.3	BARGAINING POWER OF SUPPLIERS	67
5.8.4	BARGAINING POWER OF BUYERS	67
5.8.5	INTENSITY OF COMPETITIVE RIVALRY	68
5.9	PESTLE ANALYSIS	68
5.10	REGULATORY ANALYSIS	69
TABLE 3	NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	69
TABLE 4	EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	70
TABLE 5	ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	70
TABLE 6	LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	70
TABLE 7	REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	70
5.10.1	REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	71
5.10.1.1	North America	71
5.10.1.1.1	US	71
5.10.1.1.2	Canada	71
5.10.1.2	Europe	71
5.10.1.3	Asia Pacific	71
5.10.1.3.1	China	71
5.10.1.3.2	Japan	72
5.10.1.3.3	India	72
5.10.1.4	Latin America	72
5.10.1.4.1	Brazil	72
5.10.1.4.2	Mexico	72
5.10.1.5	Middle East	73
5.10.1.6	Africa	73
5.11	TRADE ANALYSIS	73
TABLE 8	IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2018-2022 (USD MILLION)	73
TABLE 9	EXPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2018-2022 (USD MILLION)	74
5.12	TECHNOLOGY ANALYSIS	74
5.13	KEY CONFERENCES AND EVENTS, 2023-2024	75
TABLE 10	POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET: DETAILED LIST OF KEY CONFERENCES AND EVENTS	75
5.14	TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES	76
FIGURE 24	REVENUE SHIFT IN POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET	76
5.15	KEY STAKEHOLDERS AND BUYING CRITERIA	76
5.15.1	KEY STAKEHOLDERS IN BUYING PROCESS	76
FIGURE 25	INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF POINT-OF-CARE MOLECULAR DIAGNOSTICS PRODUCTS	76
TABLE 11	INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF POINT-OF-CARE MOLECULAR DIAGNOSTICS PRODUCTS	77
5.15.2	BUYING CRITERIA	77

FIGURE 26 KEY BUYING CRITERIA FOR POINT-OF-CARE MOLECULAR DIAGNOSTICS PRODUCTS 77

TABLE 12 KEY BUYING CRITERIA FOR POINT-OF-CARE MOLECULAR DIAGNOSTIC PRODUCTS 77

6 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET,

BY PRODUCT & SERVICE 78

6.1 INTRODUCTION 79

TABLE 13 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION) 80

6.2 ASSAYS & KITS 79

6.2.1 RECURRENT PURCHASES OF ASSAYS & KITS TO DRIVE GROWTH 79

TABLE 14 KEY ASSAYS & KITS AVAILABLE IN MARKET 80

TABLE 15 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR ASSAYS & KITS, BY REGION, 2021-2028 (USD MILLION) 80

6.3 INSTRUMENTS & ANALYZERS 81

6.3.1 INCREASING ADOPTION OF POC TECHNOLOGIES TO DRIVE GROWTH IN MARKET 81

TABLE 16 KEY INSTRUMENTS & ANALYZERS AVAILABLE IN MARKET 81

TABLE 17 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR INSTRUMENTS & ANALYZERS, BY REGION, 2021-2028 (USD MILLION) 82

6.4 SOFTWARE & SERVICES 82

6.4.1 GROWING UPTAKE OF ADVANCED INSTRUMENTS TO DRIVE DEMAND 82

TABLE 18 KEY SOFTWARE & SERVICES AVAILABLE IN MARKET 83

TABLE 19 POINT-OF-CARE DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY REGION, 2021-2028 (USD MILLION) 83

7 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY 84

7.1 INTRODUCTION 85

TABLE 20 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION) 85

7.2 RT-PCR 85

7.2.1 GROWING PREVALENCE OF INFECTIOUS DISEASES TO DRIVE MARKET GROWTH 85

TABLE 21 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR RT-PCR, BY REGION, 2021-2028 (USD MILLION) 86

7.3 INAAT 86

7.3.1 COST BENEFITS OF INAAT TO BOOST DEMAND 86

TABLE 22 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR INAAT, BY REGION, 2021-2028 (USD MILLION) 87

7.4 OTHER TECHNOLOGIES 87

TABLE 23 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2021-2028 (USD MILLION) 87

?

8 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION 88

8.1 INTRODUCTION 89

TABLE 24 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION) 89

8.2 RESPIRATORY DISEASES 89

8.2.1 RISING DEMAND FOR EARLY DIAGNOSIS AND DETECTION OF RESPIRATORY DISEASES TO DRIVE GROWTH 89

TABLE 25 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY DISEASES, BY REGION, 2021-2028 (USD MILLION) 90

8.3 SEXUALLY TRANSMITTED DISEASES 90

8.3.1 TECHNOLOGICAL ADVANCEMENTS FOR DETECTION OF STDs TO FAVOR MARKET GROWTH 90

TABLE 26 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY REGION, 2021-2028 (USD MILLION) 91

8.4 HOSPITAL-ACQUIRED INFECTIONS 91

8.4.1 RISING BURDEN OF MRSA TO SUPPORT GROWTH 91

TABLE 27 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY REGION, 2021-2028 (USD MILLION) 92

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

8.5 CANCER 92

8.5.1 RISING PREVALENCE OF CANCER AND GROWING FUNDING FOR CANCER RESEARCH TO DRIVE MARKET 92

TABLE 28 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR CANCER, BY REGION, 2021-2028 (USD MILLION) 93

8.6 HEPATITIS 93

8.6.1 INCREASING CASES OF HEPATITIS AMONG HIGH-RISK SUBGROUP POPULATIONS TO BOOST GROWTH 93

TABLE 29 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY REGION, 2021-2028 (USD MILLION) 94

8.7 GASTROINTESTINAL DISORDERS 94

8.7.1 GROWING INCIDENCE OF GASTROINTESTINAL DISORDERS TO PROPEL MARKET 94

TABLE 30 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR GASTROINTESTINAL DISORDERS, BY REGION, 2021-2028 (USD MILLION) 95

8.8 OTHER APPLICATIONS 95

TABLE 31 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY REGION, 2021-2028 (USD MILLION) 95

8.9 COVID-19 96

8.9.1 DECLINING CASES OF COVID-19 TO HINDER MARKET GROWTH 96

TABLE 32 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR COVID-19, BY REGION, 2021-2028 (USD MILLION) 96

?

9 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER 97

9.1 INTRODUCTION 98

TABLE 33 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION) 98

9.2 PHYSICIANS' OFFICES 98

9.2.1 FASTER RESULTS ASSOCIATED WITH POINT-OF-CARE MOLECULAR ASSAYS TO DRIVE GROWTH 98

TABLE 34 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR PHYSICIANS' OFFICES, BY REGION, 2021-2028 (USD MILLION) 99

9.3 HOSPITALS & ICUS 99

TABLE 35 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR HOSPITALS & ICUS, BY REGION, 2021-2028 (USD MILLION) 100

TABLE 36 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR HOSPITALS & ICUS, BY DISEASE TYPE, 2021-2028 (USD MILLION) 100

9.3.1 SEPSIS 100

9.3.1.1 Growing need for quick diagnosis and treatment to favor market growth 100

9.3.2 GASTROENTERITIS 101

9.3.2.1 Growing incidence of gastroenteritis cases in emergency departments to propel growth 101

9.3.3 MENINGOENCEPHALITIS 101

9.3.3.1 Severity of disease and need for early detection to drive demand 101

9.3.4 OTHER DISEASES 101

9.4 RESEARCH INSTITUTES 102

9.4.1 INCREASING USE OF POC MOLECULAR DIAGNOSTIC TESTS IN GENOMICS RESEARCH TO CONTRIBUTE TO MARKET GROWTH 102

TABLE 37 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR RESEARCH INSTITUTES, BY REGION, 2021-2028 (USD MILLION) 102

9.5 OTHER END USERS 103

TABLE 38 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2021-2028 (USD MILLION) 103

10 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY REGION 104

10.1 INTRODUCTION 105

TABLE 39 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2021-2028 (USD MILLION) 105

10.2 NORTH AMERICA 106

10.2.1 RECESSION IMPACT: NORTH AMERICA 106

FIGURE 27 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET SNAPSHOT 107

TABLE 40 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 108

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 41	NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)	108
TABLE 42	NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)	108
TABLE 43	NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)	109
TABLE 44	NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)	109
10.2.2	US	110
10.2.2.1	Growing prevalence of infectious diseases to drive market	110
TABLE 45	US: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)	110
TABLE 46	US: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)	111
TABLE 47	US: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)	111
TABLE 48	US: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)	112
10.2.3	CANADA	112
10.2.3.1	Rising government initiatives to propel market growth in coming years	112
TABLE 49	CANADA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)	113
TABLE 50	CANADA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)	113
TABLE 51	CANADA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)	113
TABLE 52	CANADA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)	114
10.3	EUROPE	114
10.3.1	RECESSION IMPACT: EUROPE	114
TABLE 53	EUROPE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)	115
TABLE 54	EUROPE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)	115
TABLE 55	EUROPE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)	115
TABLE 56	EUROPE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)	116
TABLE 57	EUROPE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)	116
10.3.2	GERMANY	117
10.3.2.1	Increasing healthcare expenditure to drive market growth in Germany	117
TABLE 58	GERMANY: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)	117
TABLE 59	GERMANY: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)	118
TABLE 60	GERMANY: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)	118
TABLE 61	GERMANY: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)	119
10.3.3	UK	119
10.3.3.1	Increasing prevalence of infectious diseases to fuel growth	119
TABLE 62	UK: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)	120
TABLE 63	UK: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)	120
TABLE 64	UK: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)	120
TABLE 65	UK: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)	121
10.3.4	FRANCE	121
10.3.4.1	Rising R&D expenditure in France to boost market	121
TABLE 66	FRANCE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)	122
TABLE 67	FRANCE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)	122
TABLE 68	FRANCE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)	122
TABLE 69	FRANCE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)	123
10.3.5	ITALY	123
10.3.5.1	Adoption of advanced diagnostic technologies to favor growth	123
TABLE 70	ITALY: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)	124
TABLE 71	ITALY: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)	124

TABLE 72	ITALY: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)	124
TABLE 73	ITALY: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)	125
10.3.6	SPAIN	125
10.3.6.1	Growing demand for genetic testing in Spain to create major growth opportunities for market players	125
TABLE 74	SPAIN: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)	125
TABLE 75	SPAIN: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)	126
TABLE 76	SPAIN: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)	126
TABLE 77	SPAIN: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)	127
10.3.7	REST OF EUROPE	127
TABLE 78	REST OF EUROPE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)	127
TABLE 79	REST OF EUROPE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)	128
TABLE 80	REST OF EUROPE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)	128
TABLE 81	REST OF EUROPE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)	129
10.4	ASIA PACIFIC	129
10.4.1	RECESSION IMPACT: ASIA PACIFIC	129
FIGURE 28	ASIA PACIFIC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET SNAPSHOT	130
TABLE 82	ASIA PACIFIC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)	131
TABLE 83	ASIA PACIFIC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)	131
TABLE 84	ASIA PACIFIC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)	131
TABLE 85	ASIA PACIFIC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)	132
TABLE 86	ASIA PACIFIC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)	132
10.4.2	CHINA	133
10.4.2.1	Growing public access to modern healthcare to drive market growth	133
TABLE 87	CHINA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)	133
TABLE 88	CHINA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)	134
TABLE 89	CHINA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)	134
TABLE 90	CHINA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)	135
10.4.3	JAPAN	135
10.4.3.1	Universal healthcare reimbursement policy to drive market growth in Japan	135
TABLE 91	JAPAN: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)	136
TABLE 92	JAPAN: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)	136
TABLE 93	JAPAN: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)	136
TABLE 94	JAPAN: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)	137
10.4.4	INDIA	137
10.4.4.1	Increasing private & public investments in healthcare system to support market growth	137
TABLE 95	INDIA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)	138
TABLE 96	INDIA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)	138
TABLE 97	INDIA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)	138
TABLE 98	INDIA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)	139
10.4.5	REST OF ASIA PACIFIC (ROAPAC)	139
TABLE 99	REST OF ASIA PACIFIC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)	140
TABLE 100	REST OF ASIA PACIFIC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)	140
TABLE 101	REST OF ASIA PACIFIC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2028 (USD	

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

MILLION) 140

TABLE 102 REST OF ASIA PACIFIC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION) 141

10.5 LATIN AMERICA 141

10.5.1 LOW PER CAPITA HEALTH SPENDING TO RESTRAIN MARKET GROWTH 141

10.5.2 RECESSION IMPACT: LATIN AMERICA 142

TABLE 103 LATIN AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION) 142

TABLE 104 LATIN AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION) 142

TABLE 105 LATIN AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION) 143

TABLE 106 LATIN AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION) 143

10.6 MIDDLE EAST & AFRICA 144

10.6.1 LACK OF SKILLED RESOURCES TO RESTRICT MARKET GROWTH 144

10.6.2 RECESSION IMPACT: MIDDLE EAST & AFRICA 144

TABLE 107 MIDDLE EAST & AFRICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION) 144

TABLE 108 MIDDLE EAST & AFRICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION) 145

TABLE 109 MIDDLE EAST & AFRICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION) 145

TABLE 110 MIDDLE EAST & AFRICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION) 146

11 COMPETITIVE LANDSCAPE 147

11.1 OVERVIEW 147

11.2 STRATEGIES OF KEY PLAYERS 147

11.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET 148

TABLE 111 OVERVIEW OF STRATEGIES DEPLOYED BY KEY POINT-OF-CARE MOLECULAR DIAGNOSTICS MANUFACTURING COMPANIES 148

11.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS 149

FIGURE 29 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET (2018-2022) 149

11.4 MARKET SHARE ANALYSIS 150

FIGURE 30 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET SHARE, BY KEY PLAYER (2022) 150

TABLE 112 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET SHARE: DEGREE OF COMPETITION 150

11.5 COMPANY EVALUATION QUADRANT 151

11.5.1 LIST OF EVALUATED VENDORS 151

11.5.2 STARS 151

11.5.3 EMERGING LEADERS 151

11.5.4 PERVASIVE PLAYERS 151

11.5.5 PARTICIPANTS 152

FIGURE 31 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET: COMPETITIVE LEADERSHIP MAPPING, 2022 152

11.6 COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/SMES (2022) 153

11.6.1 PROGRESSIVE COMPANIES 153

11.6.2 STARTING BLOCKS 153

11.6.3 RESPONSIVE COMPANIES 153

11.6.4 DYNAMIC COMPANIES 153

FIGURE 32 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET: COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/SMES, 2022 154

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

11.7	COMPETITIVE BENCHMARKING	155
11.7.1	PRODUCT AND REGIONAL FOOTPRINT ANALYSIS	155
FIGURE 33	PRODUCT & SERVICE AND REGIONAL FOOTPRINT ANALYSIS OF TOP PLAYERS IN POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET	155
TABLE 113	POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET: COMPANY REGIONAL FOOTPRINT	155
TABLE 114	POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET: COMPANY PRODUCT & SERVICE FOOTPRINT	155
TABLE 115	POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET: DETAILED LIST OF KEY START-UPS/SMES	156
11.8	COMPETITIVE SCENARIO	157
11.8.1	PRODUCT LAUNCHES & APPROVALS	157
TABLE 116	KEY PRODUCT LAUNCHES & APPROVALS	157
11.8.2	DEALS	158
TABLE 117	KEY DEALS	158
12	COMPANY PROFILES	159
12.1	KEY PLAYERS	159
	(Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)*	
12.1.1	ABBOTT LABORATORIES	159
TABLE 118	ABBOTT LABORATORIES: BUSINESS OVERVIEW	159
FIGURE 34	ABBOTT LABORATORIES: COMPANY SNAPSHOT (2022)	160
12.1.2	F. HOFFMANN-LA ROCHE LTD.	163
TABLE 119	F. HOFFMANN-LA ROCHE LTD.: BUSINESS OVERVIEW	163
FIGURE 35	F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2022)	164
12.1.3	BIOMERIEUX SA	167
TABLE 120	BIOMERIEUX SA: BUSINESS OVERVIEW	167
FIGURE 36	BIOMERIEUX SA: COMPANY SNAPSHOT (2022)	168
12.1.4	DANAHER CORPORATION	171
TABLE 121	DANAHER CORPORATION: BUSINESS OVERVIEW	171
FIGURE 37	DANAHER CORPORATION: COMPANY SNAPSHOT (2022)	172
12.1.5	QIAGEN N.V.	175
TABLE 122	QIAGEN N.V.: BUSINESS OVERVIEW	175
FIGURE 38	QIAGEN N.V.: COMPANY SNAPSHOT (2022)	176
12.1.6	QUIDELORTHO CORPORATION	179
TABLE 123	QUIDELORTHO CORPORATION: BUSINESS OVERVIEW	179
FIGURE 39	QUIDELORTHO CORPORATION: COMPANY SNAPSHOT (2022)	180
12.1.7	CO-DIAGNOSTICS, INC.	182
TABLE 124	CO-DIAGNOSTICS INC.: BUSINESS OVERVIEW	182
FIGURE 40	CO-DIAGNOSTICS, INC.: COMPANY SNAPSHOT (2022)	182
12.1.8	BIOCARTIS NV	185
TABLE 125	BIOCARTIS NV: BUSINESS OVERVIEW	185
FIGURE 41	BIOCARTIS NV: COMPANY SNAPSHOT (2022)	186
12.1.9	MERIDIAN BIOSCIENCE, INC.	189
TABLE 126	MERIDIAN BIOSCIENCE, INC.: BUSINESS OVERVIEW	189
FIGURE 42	MERIDIAN BIOSCIENCE, INC.: COMPANY SNAPSHOT (2022)	190
12.1.10	THERMO FISHER SCIENTIFIC INC.	193
TABLE 127	THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW	193
FIGURE 43	THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2022)	194

*Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made,

Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.

12.2 OTHER PLAYERS 196

12.2.1 LUCIRA HEALTH, INC. 196

12.2.2 CUE HEALTH 197

12.2.3 OPGEN, INC. 197

12.2.4 BINX HEALTH, INC. 198

12.2.5 MOLBIO DIAGNOSTICS PVT. LTD. 198

12.2.6 GENOMADIX 200

12.2.7 VISBY MEDICAL, INC. 200

12.2.8 QUIKPATH PTE. LTD. 201

12.2.9 MD-BIO 201

12.2.10 QUANTUMDX GROUP LTD. 201

12.2.11 AIDIAN OY 202

12.2.12 GENESTAT MOLECULAR DIAGNOSTICS, LLC. 202

12.2.13 LABSYSTEMS DIAGNOSTICS OY 203

12.2.14 AKONNI BIOSYSTEMS 203

12.2.15 CURETIS N.V. 204

?

13 APPENDIX 205

13.1 DISCUSSION GUIDE 205

13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL 209

13.3 AVAILABLE CUSTOMIZATIONS 211

13.4 RELATED REPORTS 211

13.5 AUTHOR DETAILS 212

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Point of Care Molecular Diagnostics Market by Product (Assays, Kits, Instruments, Software), Application (Respiratory Diseases, HAIs, Cancer, STDs, Hepatitis), Technology (RT-PCR, INAAT), End User (Clinics, Hospitals, ICUs) - Global Forecast to 2028

Market Report | 2023-06-14 | 207 pages | MarketsandMarkets

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User	\$4950.00
	Multi User	\$6650.00
	Corporate License	\$8150.00
	Enterprise Site License	\$10000.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	2025-05-20
		Signature	<div></div>